Does mycophenolic acid suppress lymphocyte proliferation and reduce immunoglobulin responses?

Mycophenolic acid (MPA) is a cornerstone immunosuppressant that precisely targets lymphocyte replication and humoral immune responses, making its pharmacology highly relevant for managing autoimmune diseases and transplant rejection.

Cellular and molecular mechanisms

• Enzymatic inhibition: MPA acts as a potent, reversible, and uncompetitive inhibitor of mammalian inosine monophosphate dehydrogenase (IMPDH). It specifically targets the type II isoform upregulated in activated immune cells, demonstrating a low inhibition constant ($K_i$) of 20 to 30 nM.
• Nucleotide depletion: By blocking the conversion of IMP to xanthosine monophosphate (XMP), MPA depletes essential intracellular guanosine nucleotide pools (GMP, GTP, and dGTP).
• Selective cytostasis: Because T and B lymphocytes rely almost exclusively on de novo purine synthesis rather than salvage pathways, this depletion selectively halts their cell cycle at the G1-S phase, suppressing proliferation with an $IC_{50}$ of 0.1 to 0.3 mg/L.

Humoral response and clinical safety

• Immunoglobulin suppression: MPA significantly blunts humoral immunity, frequently causing secondary hypogammaglobulinemia. This is primarily characterized by a profound, dose-dependent reduction in serum immunoglobulin G (IgG) levels, and occasionally IgM and IgA.
• Clinical implications: The targeted suppression of T- and B-cell clonal expansion directly compromises antibody production. For older patients, such as a 75-year-old female, this decline in IgG can substantially elevate the risk of recurrent respiratory or urinary tract infections, requiring careful clinical monitoring of serum immunoglobulins.

Bottom line

Mycophenolic acid selectively suppresses lymphocyte proliferation by inhibiting IMPDH ($K_i$ 20–30 nM) and depleting guanosine pools, which secondarily reduces immunoglobulin levels (primarily IgG) and increases susceptibility to infection.